

+49 89 45563 999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/727,566
Applicant : STAELHLER et al
Filed : December 5, 2003
TC/A.U. : 1639
Examiner : My Chau T Tran

Docket No. : 2923-593
Customer No. : 6449
Confirmation No. : 7975

TERMINAL DISCLAIMER TO OBLIGATE A PROVISIONAL
DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The owner, febit biotech GmbH, of Heidelberg, Germany owns 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Serial No. 10/399,450, filed on August 1, 2003, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

+49 89 45563 999

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Statement under 37 C.F.R. 3.73(b)

febit biotech GmbH is the assignee of 100 percent interest in the instant application, by virtue of an assignment recorded of even date in the U.S. Patent and Trademark Office.

The undersigned, whose title is supplied below, is empowered to act on behalf of the owner.

Declaration

The undersigned hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


+49 89 45563 999

febit biotech GmbH

febit biotech gmbh febit

Im Neuenheimer Feld 519
69120 Heidelberg
Germanyphone +49 06221 6510 300
fax +49 06221 6510 329
e-mail info@febit.de

By:



Signature

Typed Name: Carsten Staehle

Typed Title: CEO / Geschäftsführer

Date: 14/05/2007